clinical trial · NCT00617695
Efficacy of Zolmitriptan (Zomig) in the Treatment of Migraines in Adolescents
Impax Laboratories, LLC·phase3·completed·n = 247
MigraineZolmitriptanPlacebo
brief summary
The purpose of this study is to evaluate the effectiveness and safety of Zolmitriptan (Zomig) nasal spray, 5.0 mg, compared with placebo (inactive drug) for 2 migraine headaches over a 3-month period in adolescent patients (aged 12 to 17 years) with migraine headaches
started
Sep 1, 2003
primary completion
—
completion
Oct 1, 2004
last updated
Oct 2, 2024
official title
A Multicenter, Double-blind, Randomized, Placebo-controlled, 2-way Crossover Study With Single-blind, Placebo-challenge Evaluating the Efficacy of Zolmitriptan (Zomig) Nasal Spray 5mg, in the Treatment of Acute Migraine Headache in Adolescents.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol